ArticleThe journal of headache and pain2019

An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.

Fayyaz Ahmed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.